PRG2505

PRG2505 (also known as V001 Injection) is an investigational *in vivo* chimeric antigen receptor T-cell (CAR-T) therapy. Developed by Pregene Biotech, it represents a significant shift from traditional CAR-T therapies by utilizing a delivery vector to genetically modify a patient's T cells directly within their own body. This *in vivo* approach aims to bypass the complex, costly, and time-consuming *ex vivo* manufacturing processes typically required for CAR-T cell production. By generating CAR-T cells internally, the therapy seeks to reduce the time to treatment and improve patient access. PRG2505 is currently being evaluated in clinical trials, including the PLATFORM2 phase I/II study sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, specifically targeting patients with advanced and rare solid tumors who have limited standard treatment options.

Other names

V001 InjectionV-001 InjectionV 001 Injection